Clinical Trial Update: Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating adoptive transfer of invariant natural killer T (iNKT) cells combined with TAE/TACE for unresectable hepatocellular carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• iNKT cell therapy (invariant natural killer T cell adoptive transfer)

Snippet

Sponsor: Beijing YouAn Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-08